January 20, 2017
Agile Therapeutics Inc. misled investors into thinking that a contraceptive patch it was developing would get U.S. Food and Drug Administration approval, even though more than half the participants had dropped out of the clinical study and the patch didn't meet industry standards, a second potential class of shareholders alleged in New Jersey federal court on Friday.